124 related articles for article (PubMed ID: 19864122)
21. The topical niacin sensitivity test: an inter- and intra-rater reliability study in healthy controls.
Kerr M; Cotton S; Proffitt T; McConchie M; Markulev C; Smesny S; McGorry P; Berger G
Prostaglandins Leukot Essent Fatty Acids; 2008; 79(1-2):15-9. PubMed ID: 18656334
[TBL] [Abstract][Full Text] [Related]
22. Lateralized electrodermal dysfunction and complexity in patients with schizophrenia and depression.
Bob P; Susta M; Glaslova K; Pavlat J; Raboch J
Neuro Endocrinol Lett; 2007 Feb; 28(1):11-5. PubMed ID: 17277732
[TBL] [Abstract][Full Text] [Related]
23. Niacin skin flush is not diagnostic of schizophrenia.
Wilson DW; Douglass AB
Biol Psychiatry; 1986 Aug; 21(10):974-7. PubMed ID: 3741914
[No Abstract] [Full Text] [Related]
24. Autonomic abnormalities in schizophrenia. State or trait indicators?
Dawson ME; Nuechterlein KH; Schell AM; Gitlin M; Ventura J
Arch Gen Psychiatry; 1994 Oct; 51(10):813-24. PubMed ID: 7944871
[TBL] [Abstract][Full Text] [Related]
25. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study.
Messamore E; Hoffman WF; Janowsky A
Schizophr Res; 2003 Aug; 62(3):251-8. PubMed ID: 12837522
[TBL] [Abstract][Full Text] [Related]
26. Defense Mechanism Test and electrodermal activity.
Bogren L; Bogren IB; Thorell LH
Percept Mot Skills; 1998 Aug; 87(1):279-90. PubMed ID: 9760659
[TBL] [Abstract][Full Text] [Related]
27. Niacin test in schizophrenia and affective illness.
Rybakowski J; Weterle R
Biol Psychiatry; 1991 Apr; 29(8):834-6. PubMed ID: 2054456
[No Abstract] [Full Text] [Related]
28. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia.
Smesny S; Rosburg T; Baur K; Rudolph N; Sauer H
Neuropsychopharmacology; 2007 Oct; 32(10):2067-73. PubMed ID: 17314920
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in PLA2G6 and PLA2G4C genes for calcium-independent phospholipase A2 do not contribute to attenuated niacin skin flush response in schizophrenia patients.
Nadalin S; Radović I; Buretić-Tomljanović A
Prostaglandins Leukot Essent Fatty Acids; 2015 Sep; 100():29-32. PubMed ID: 26160611
[TBL] [Abstract][Full Text] [Related]
30. What does electrodermal activity tell us about prognosis in the schizophrenia spectrum?
Dawson ME; Schell AM
Schizophr Res; 2002 Mar; 54(1-2):87-93. PubMed ID: 11853982
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and Specificity of the Abnormal Niacin Response: A Potential Endophenotype Marker in Schizophrenia.
Yao JK; Dougherty GG; Gautier CH; Haas GL; Condray R; Kasckow JW; Kisslinger BL; Gurklis JA; Messamore E
Schizophr Bull; 2016 Mar; 42(2):369-76. PubMed ID: 26371338
[TBL] [Abstract][Full Text] [Related]
32. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading.
Chang SS; Liu CM; Lin SH; Hwu HG; Hwang TJ; Liu SK; Hsieh MH; Guo SC; Chen WJ
Schizophr Bull; 2009 Jan; 35(1):213-21. PubMed ID: 18203758
[TBL] [Abstract][Full Text] [Related]
33. Neuroanatomical bases of electrodermal hypo-responding: a cluster analytic study.
Lencz T; Raine A; Sheard C
Int J Psychophysiol; 1996; 22(3):141-53. PubMed ID: 8835622
[TBL] [Abstract][Full Text] [Related]
34. Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population.
Sun L; Yang X; Jiang J; Hu X; Qing Y; Wang D; Yang T; Yang C; Zhang J; Yang P; Wang P; Cai C; Wang J; He L; Wan C
Schizophr Bull; 2018 Jun; 44(4):896-907. PubMed ID: 29077970
[TBL] [Abstract][Full Text] [Related]
35. The effect of niacin on facial blood flow in people with an elevated fear of negative evaluation.
Drummond PD; Lazaroo D
Eur Neuropsychopharmacol; 2012 Mar; 22(3):200-4. PubMed ID: 21856131
[TBL] [Abstract][Full Text] [Related]
36. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?
Hudson CJ; Lin A; Cogan S; Cashman F; Warsh JJ
Biol Psychiatry; 1997 Mar; 41(5):507-13. PubMed ID: 9046982
[TBL] [Abstract][Full Text] [Related]
37. Response time and electrodermal measures in chronic schizophrenia: the effects of chlorpromazine.
Pugh LA
J Nerv Ment Dis; 1968 Jan; 146(1):62-70. PubMed ID: 5648860
[No Abstract] [Full Text] [Related]
38. Niacin sensitivity and the arachidonic acid pathway in schizophrenia.
Messamore E; Hoffman WF; Yao JK
Schizophr Res; 2010 Sep; 122(1-3):248-56. PubMed ID: 20417059
[TBL] [Abstract][Full Text] [Related]
39. Effects of neuroleptics on electrodermal activity in schizophrenic patients: a review.
Schnur DB
Psychopharmacology (Berl); 1990; 102(4):429-37. PubMed ID: 1982901
[TBL] [Abstract][Full Text] [Related]
40. Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship.
Yu YH; Su HM; Lin SH; Hsiao PC; Lin YT; Liu CM; Hwang TJ; Hsieh MH; Liu CC; Chien YL; Kuo CJ; Hwu HG; Chen WJ
Schizophrenia (Heidelb); 2022 Apr; 8(1):38. PubMed ID: 35853900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
